Display options
Cite
Hamaoka T, Murai H, Hirai T, et al. Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure. J Am Heart Assoc. 2021;10(22):e022637doi: 10.1161/JAHA.121.022637.
Hamaoka, T., Murai, H., Hirai, T., Sugimoto, H., Mukai, Y., Inoue, O., Takashima, S., Kato, T., Takata, S., Usui, S., Sakata, K., Kawashiri, M. A., & Takamura, M. (2021). Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure. Journal of the American Heart Association, 10(22), e022637. https://doi.org/10.1161/JAHA.121.022637
Hamaoka, Takuto, et al. "Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure." Journal of the American Heart Association vol. 10,22 (2021): e022637. doi: https://doi.org/10.1161/JAHA.121.022637
Hamaoka T, Murai H, Hirai T, Sugimoto H, Mukai Y, Inoue O, Takashima S, Kato T, Takata S, Usui S, Sakata K, Kawashiri MA, Takamura M. Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure. J Am Heart Assoc. 2021 Nov 16;10(22):e022637. doi: 10.1161/JAHA.121.022637. Epub 2021 Oct 30. PMID: 34719241.
Copy Download .nbib Format: NLM
Share it on

J Am Heart Assoc. 2021 Nov 16;10(22):e022637. doi: 10.1161/JAHA.121.022637. Epub 2021 Oct 30.

Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure.

Journal of the American Heart Association

Takuto Hamaoka, Hisayoshi Murai, Tadayuki Hirai, Hiroyuki Sugimoto, Yusuke Mukai, Oto Inoue, Shinichiro Takashima, Takeshi Kato, Shigeo Takata, Soichiro Usui, Kenji Sakata, Masa-Aki Kawashiri, Masayuki Takamura

Affiliations

  1. Department of Cardiovascular Medicine Kanazawa University Graduate School of Medical Sciences Kanazawa Japan.
  2. Kanazawa Municipal Hospital Kanazawa Japan.

PMID: 34719241 DOI: 10.1161/JAHA.121.022637

Abstract

Background Sodium-glucose cotransporter 2 inhibitors improve cardiovascular outcomes in patients with diabetes with and without heart failure (HF). However, their influence on sympathetic nerve activity (SNA) remains unclear. The purpose of this study was to evaluate the effect of sodium-glucose cotransporter 2 inhibitors on SNA and compare the responses of SNA to sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes with and without HF. Methods and Results Eighteen patients with type 2 diabetes, 10 with HF (65.4±3.68 years) and 8 without HF (63.3±3.62 years), were included. Muscle SNA (MSNA), heart rate, and blood pressure were recorded before and 12 weeks after administration of dapagliflozin (5 mg/day). Sympathetic and cardiovagal baroreflex sensitivity were simultaneously calculated. Brain natriuretic peptide level increased significantly at baseline in patients with HF than those without HF, while MSNA, blood pressure, and hemoglobin A1c did not differ between the 2 groups. Fasting blood glucose and homeostatic model assessment of insulin resistance did not change in either group after administering dapagliflozin. MSNA decreased significantly in both groups. However, the reduction in MSNA was significantly higher in patients with HF than patients with non-HF (-20.2±3.46 versus -9.38±3.65 bursts/100 heartbeats;

Keywords: baroreflex sensitivity; diabetes mellitus; heart failure; muscle sympathetic nerve activity

Publication Types